Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.
Journal articles
- Journal Article
Srinagesh, HK; Gupta, V; Zhang, A; Grunwald, M; Connor, M; Kota, VK; Boccucci, J; Ulrickson, M; Pradeep, R; Hill, L; Tsai, SB; O'Connor, T ...
Published in: Blood
April 23, 2026
In a real-world analysis of brexucabtagene autoleucel recipients with relapsed/refractory B-cell acute lymphoblastic leukemia (N = 278), lack of response to prior blinatumomab correlates with significantly worse following chimeric antigen receptor T-cell therapy outcomes.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Blood
DOI
EISSN
1528-0020
Publication Date
April 23, 2026
Volume
147
Issue
17
Start / End Page
2011 / 2017
Location
United States
Related Subject Headings
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Immunology
- Humans
- Antibodies, Bispecific
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
Citation
APA
Chicago
ICMJE
MLA
NLM
Srinagesh, H. K., Gupta, V., Zhang, A., Grunwald, M., Connor, M., Kota, V. K., … Muffly, L. S. (2026). Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL. Blood, 147(17), 2011–2017. https://doi.org/10.1182/blood.2025031734
Srinagesh, Hrishikesh K., Vishal Gupta, Amy Zhang, Michael Grunwald, Matthew Connor, Vamsi K. Kota, Jacob Boccucci, et al. “Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.” Blood 147, no. 17 (April 23, 2026): 2011–17. https://doi.org/10.1182/blood.2025031734.
Srinagesh HK, Gupta V, Zhang A, Grunwald M, Connor M, Kota VK, et al. Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL. Blood. 2026 Apr 23;147(17):2011–7.
Srinagesh, Hrishikesh K., et al. “Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.” Blood, vol. 147, no. 17, Apr. 2026, pp. 2011–17. Pubmed, doi:10.1182/blood.2025031734.
Srinagesh HK, Gupta V, Zhang A, Grunwald M, Connor M, Kota VK, Boccucci J, Ulrickson M, Pradeep R, Hill L, Tsai SB, O’Connor T, Sandhu K, Advani AS, Reshef R, Gordillo CA, Luskin MR, Chen EC, Lin C, Cassaday RD, Kopmar NE, Majhail NS, Battiwalla M, Strickland SA, Lee CJ, Bobillo SO, Hilal T, Park JH, Valtis YK, Faramand R, Solh MM, Guzowski C, Vasu S, Leonard JT, Tan V, Wang ES, McCauley R, Sasine J, Tang K, Miller K, Sutherland KC, Daunov M, Mohty R, Jamy O, Kumaran MV, Hoeg RT, Dykes KC, Logan AC, Othman T, Stock W, Schwartz M, Byrd K, Yalniz F, Bachanova V, Tracy S, Yaghmour G, Irizarry Gatell VM, Jackson CW, Oluwole OO, Dholaria B, O’Dwyer KM, Moore J, Roloff GW, Frey NV, Aldoss I, Shah BD, Oliai CH, Muffly LS. Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL. Blood. 2026 Apr 23;147(17):2011–2017.
Published In
Blood
DOI
EISSN
1528-0020
Publication Date
April 23, 2026
Volume
147
Issue
17
Start / End Page
2011 / 2017
Location
United States
Related Subject Headings
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Immunology
- Humans
- Antibodies, Bispecific
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology